Overview

Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Alogliptin